News
-
-
PRESS RELEASE
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
New patent issued for core rare disease target indication for crofelemer by Jaguar Health, enhancing intellectual property protection. Proof-of-concept studies ongoing for SBS and MVID -
-
PRESS RELEASE
Jaguar Health Reports Second Quarter 2024 Financial Results
Jaguar Health, Inc. reports a 16% revenue increase in Q2 2024 for prescription and non-prescription products. Company explores approval pathways for crofelemer in rare diseases, plans commercial launch of Gelclair in October 2024 -
-
PRESS RELEASE
Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
Napo Pharmaceuticals announced positive results of studies on crofelemer for chronic refractory diarrhea at the ACG Annual Scientific Meeting. The drug may benefit patients with functional diarrhea and chronic idiopathic diarrhea -
-
PRESS RELEASE
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
New patent issued for core rare disease target indication for crofelemer. European Patent Office grants Napo Pharmaceuticals patent to use crofelemer for congenital diarrheal disorders (CDDs). Jaguar supports studies in SBS and MVID, with results by 2025 -
-
PRESS RELEASE
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
Jaguar Health, Inc. announces initial results from Phase 3 OnTarget trial of crofelemer for cancer patients' diarrhea prophylaxis. Positive signals for breast and respiratory cancer subgroups in multicenter, double-blind study
